◼ Archived
Business
Ultragenyx shrinks workforce and axes assets to halve R&D spend
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 trends tracked about this subject — the full history, oldest to newest below.
4 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
FDA approves Ultragenyx's gene therapy Fayuvi for Sanfilippo syndrome at a price of $3.95 million.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.